Jasper Therapeutics: William Blair resumes coverage with outperform rating
JSPR•William Blair resumed coverage of Jasper Therapeutics with an outperform rating.
Related News
NeOnc names FAB Islamic Banking head Ali Alabedin to board
NTHI•
Cushman & Wakefield prepares Norfin Group sustainability report for FY2025
CWK•
MindWalk names Zachary Maben director of antigen discovery, protein engineering
HYFT•
Tempest Therapeutics appoints John W. Frederick to board of directors
TPST•
Aquestive rises on US licensing deal for seizure drug with Eton Pharma
AQST•